SPONSOR
OHSU Knight Cancer Institute
Total Trials
5
Recruiting
5
Phases
Phase 1, Phase 2, Phase 1, Phase 2
Conditions studied: Familial Platelet Disorder With Associated Myeloid MalignancyChronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell LymphomaMultiple MyelomaPrimary Mediastinal Large B-Cell LymphomaSmall Lymphocytic LymphomaIDH Wild Type GlioblastomaAdvanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Familial Platelet Disorder With Associated Myeloid Malignancy, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma.
The trial portfolio spans Phase 1, Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — OHSU Knight Cancer Institute
How many clinical trials has OHSU Knight Cancer Institute sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by OHSU Knight Cancer Institute, of which 5 are actively recruiting participants. These trials cover conditions including Familial Platelet Disorder With Associated Myeloid Malignancy, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does OHSU Knight Cancer Institute research focus on?
OHSU Knight Cancer Institute clinical trials span Familial Platelet Disorder With Associated Myeloid Malignancy, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a OHSU Knight Cancer Institute clinical trial?
To participate in a OHSU Knight Cancer Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all OHSU Knight Cancer Institute trials with current recruitment status updated daily.
Clinical Trials by OHSU Knight Cancer Institute
NCT07844694 Phase 1
Recruiting
Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder
Familial Platelet Disorder With Associated Myeloid Malignancy
NCT06784167
Recruiting
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Chronic Lymphocytic Leukemia
NCT03649880 Phase 2
Recruiting
Feasibility of FMISO in Brain Tumors
IDH Wild Type Glioblastoma
NCT06320405 Phase 1, Phase 2
Recruiting
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Advanced Malignant Solid Neoplasm
NCT04659616 Phase 1
Recruiting
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology